UPDATE: Stifel Reiterates Buy Rating, Raises PT on HealthSouth Corp. as Second Quarter Easily Exceeds Projection

In a report published Tuesday, Stifel analyst Robert Mains reiterated a Buy rating on HealthSouth Corp. HLS, and raised the price target from $38.00 to $41.00. In the report, Stifel noted, “HealthSouth reported second quarter earnings well ahead of our estimate. The company reported income from continuing operations per share (its EPS proxy) of $0.81, beating our $0.65 estimate. Excluding an accounting gain, income from continuing operations per share were $0.54 compared to our at-consensus $0.48 estimate. We are raising our earnings estimate and target price, as the company also increased its guidance.” HealthSouth Corp. closed on Monday at $37.64.